March 2025
PrIMAVeRa partners came together in Utrecht, The Netherlands, for a workshop held on 5-6 March. Organised by the University Medical Center Utrecht, the meeting was filled with intensive scientific discussions centred around identifying strategies to best refine and expand the mathematical models that will power the platform being developed. Partners also discussed how to most effectively utilise the available data to populate the models. This will facilitate better evaluation of the cost-effectiveness of various vaccination strategies and monoclonal antibody interventions aimed toward the reduction of antimicrobial resistance (AMR).
To refine the path forward, the team debated topics including tailoring modelling approaches to specific pathogens, antibiotic consumption and its relation to AMR, the necessity of stratified data for use within health economic models, the pilot countries selected to perform evaluation of the models’ accuracy, and other issues crucial to achieving the goals of PrIMAVeRa.
The workshop ended with decisions taken on the next steps for each of the models being developed, and with renewed focus on continuing the fight against this global threat to public health.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.